Kerr KM, Bubendorf L, Lopez-Rios F, Khalil F, Roy-Chowdhuri S, Joubert P, Hartmann A, Guerini-Rocco E, Yatabe Y, Hofman P, Cooper WA, Dacic S (2024)
Publication Type: Journal article, Review article
Publication year: 2024
Book Volume: 84
Pages Range: 429-439
Journal Issue: 3
DOI: 10.1111/his.15078
Many patients with non-small cell lung cancer do not receive guideline-recommended, biomarker-directed therapy, despite the potential for improved clinical outcomes. Access to timely, accurate, and comprehensive molecular profiling, including targetable protein overexpression, is essential to allow fully informed treatment decisions to be taken. In turn, this requires optimal tissue management to protect and maximize the use of this precious finite resource. Here, a group of leading thoracic pathologists recommend factors to consider for optimal tissue management. Starting from when lung cancer is first suspected, keeping predictive biomarker testing in the front of the mind should drive the development of practices and procedures that conserve tissue appropriately to support molecular characterization and treatment selection.
APA:
Kerr, K.M., Bubendorf, L., Lopez-Rios, F., Khalil, F., Roy-Chowdhuri, S., Joubert, P.,... Dacic, S. (2024). Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists. Histopathology, 84(3), 429-439. https://doi.org/10.1111/his.15078
MLA:
Kerr, Keith M., et al. "Optimizing tissue stewardship in non-small cell lung cancer to support molecular characterization and treatment selection: statement from a working group of thoracic pathologists." Histopathology 84.3 (2024): 429-439.
BibTeX: Download